Reference : Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents
Scientific journals : Article
Human health sciences : Oncology
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/4700
Evaluation of original dual thromboxane A2 modulators as antiangiogenic agents
English
de Leval, Xavier [> > > >]
Dassesse, Thibaut [> > > >]
Dogné, Jean-Michel [Université de Liège - ULg > Département de pharmacie > Département de pharmacie >]
Waltregny, David mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases >]
Bellahcene, Akeila mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Labo de recherche sur les métastases >]
Benoit, Valérie [> > > >]
Pirotte, Bernard mailto [Université de Liège - ULg > > Chimie pharmaceutique >]
Castronovo, Vincenzo mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire >]
Sep-2006
Journal of Pharmacology and Experimental Therapeutics (The)
Amer Soc Pharmacology Experimental Therapeutics
318
3
1057-1067
Yes (verified by ORBi)
International
0022-3565
Bethesda
[en] Thromboxane ; endothelial cell
[en] Angiogenesis is a promising target for the therapy of several diseases including cancer. This study was undertaken to characterize the antiangiogenic properties of a series of original dual thromboxane A(2) (TXA(2)) inhibitors derived from torasemide, a marketed loop diuretic with TXA(2) antagonistic properties, by evaluating their effects on human endothelial cell migration, adhesion, and viability in vitro, as well as in the ex vivo rat aortic ring assay. All drugs tested exhibited a marked affinity toward human platelet TXA(2) receptor, significantly prevented platelet aggregation induced by U-46,619, a stable TXA(2) receptor agonist, and inhibited platelet TXA(2) synthase without affecting cyclooxygenase (COX)-1 or COX-2 enzymatic activities. These dual TXA(2) inhibitors dose dependently inhibited endothelial cell migration in chemotaxis assays using vascular endothelial growth factor ( VEGF) as a chemoattractant but failed to affect cell adhesion and viability. The highest rates of cell migration inhibition were obtained with original compounds BM-567 and BM-573 (50.3 and 59.4% inhibition, respectively) when used at the final concentration of 10 mu M. In addition, pretreatment of endothelial cells with these two drugs significantly prevented U-46,619-induced intracellular Ca2+ pool mobilization, thus suggesting a mechanistic link between inhibition of the TXA(2) pathway and reduced endothelial cell migration. Treatment of rat aortic explants with U-46,619 (9,11- dideoxy- 9,11- methanoepoxyprostaglandin F 2) significantly enhanced vessel sprouting whereas aortic rings treated with some of the compounds, including BM-567 (N-n-pentyl-N'-[2-(cyclohexylamino)-5-nitrobenzenesulfonyl] urea) and BM-573 (N-tert-butyl-N'-[5-nitro-2p- toluylaminobenzenesulfonyl]urea), showed a significant decrease in vessel sprouting, which was not reversed by the addition of VEGF. These data suggest that our original dual TXA(2) inhibitors bear antiangiogenic properties, mainly by inhibiting endothelial cell migration.
Researchers ; Professionals
http://hdl.handle.net/2268/4700
also: http://hdl.handle.net/2268/23358
10.1124/jpet.106.101188

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Pub#45 JPET TXA2 2006.pdfNo commentaryPublisher postprint423.11 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.